A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

PURPOSE: The REal life assessmENt of safety And effeCTiveness of Razumab 2 (RE-ENACT 2) study evaluated the long-term effectiveness of biosimilar ranibizumab. We present the subgroup analysis of patients with retinal vein occlusion (RVO). METHODS: Data of patients who received pro re nata (PRN) bios...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shashikant, Khan, Mujtaba, Chaturvedi, Alok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406620/
https://www.ncbi.nlm.nih.gov/pubmed/32617913
http://dx.doi.org/10.1007/s40123-020-00277-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406620/
https://www.ncbi.nlm.nih.gov/pubmed/32617913
http://dx.doi.org/10.1007/s40123-020-00277-3

Ejemplares similares